Sandoz Group AG Q2 2026 Earnings Recap

SDZ.SW Q2 2026 August 10, 2026

Get alerts when SDZ.SW reports next quarter

Sandoz shares rose 7.7% following its H1 earnings as biosimilar sales outpaced expectations, driving robust top-line growth and margin expansion. Confidence in the 2026 guidance and strong commercial execution across key portfolios supported the positive reaction.

Earnings Per Share Miss

$1.38 vs $1.41 est.

-2.1% surprise

Revenue Beat

4660726000 vs 4656411000 est.

+0.1% surprise

Market Reaction

1-Day -0.28%

See SDZ.SW alongside your other holdings

Add to your portfolio — free

Key Takeaways

Net sales increased 5% in H1, accelerating to 7% growth in Q2, led by a 20% rise in biosimilars (22% growth in Q2).
Biosimilars now represent 33% of net sales, underpinned by successful launches such as Wyost and Jubbonti capturing market leadership in the U.S. and Europe.
Core EBITDA margin expanded by 90 basis points to 20.9%, reflecting operational leverage despite increased CapEx.
Management free cash flow remained strong at approximately $500 million in the period.
No changes to 2026 guidance were made, signaling confidence in sustained growth amid ongoing regulatory and pipeline progress.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit SDZ.SW on AllInvestView.